 |
fixed dose combination formulation of macitentan and tadalafil |
|---|---|
| Trade Name | |
| Orphan Indication | Pulmonary Arterial Hypertension |
| USA Market Approval | USA |
| USA Designation Date | 2016-10-19 00:00:00 |
| Sponsor | Actelion Clinical Research, Inc.;1820 Chapel Avenue West, Suite 300;Cherry Hill, New Jersey, 08002 |
